Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris Inc. (NASDAQ: VTRS) announced a 9% increase in its quarterly dividend, now set at 12 cents ($0.12) per share, payable on March 16, 2022. This marks the fourth consecutive quarterly dividend declaration, positioning the annual dividend rate for 2022 at 48 cents ($0.48) per share. CEO Michael Goettler expressed satisfaction with the company's operational momentum and commitment to returning capital to shareholders. The record date for this dividend is February 24, 2022.
Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Patent and Trademark Appeal Board affirmed its previous rulings declaring several of Sanofi's Lantus® SoloSTAR® device patents unpatentable. This decision is a significant win for Viatris, facilitating wider access to its interchangeable Semglee® products, which are now the only interchangeable biosimilars for Lantus®. These products aim to provide affordable insulin options for diabetes patients, allowing substitution at pharmacies. Viatris' commitment to enhancing patient access is evident through its Global Healthcare Gateway® initiative.
Viatris Inc. (NASDAQ: VTRS) has announced a rescheduling of its investor event from January 7, 2022, to a date no later than February 28, 2022, coinciding with the release of its fourth quarter 2021 results. The company reaffirmed its 2021 financial guidance originally provided on November 8, 2021. During the event, Viatris will present details on its two-phased strategic roadmap, covering financial guidance and metrics for Phase I (2022-2023) and growth catalysts for Phase II (2024 and beyond), including capital allocation priorities and pipeline developments.
On December 1, 2021, Viatris (NASDAQ: VTRS) announced that the U.S. Court of Appeals affirmed a prior ruling that invalidated Biogen's Tecfidera patent for lack of written description. This decision supports Viatris' launch of a generic version of Tecfidera in August 2020, facilitating greater access to multiple sclerosis treatments. CEO Michael Goettler expressed satisfaction with the ruling, highlighting Viatris' commitment to improving patient access to affordable medications.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 7:30 a.m. ET. Executives Michael Goettler, Rajiv Malik, and Sanjeev Narula will engage in a discussion regarding company insights. Investors can access the live webcast at investor.viatris.com. An archived version will also be available post-event. Viatris aims to empower global healthcare access and provides over 1,400 approved molecules in diverse therapeutic areas.
Viatris (NASDAQ: VTRS) and Biocon Biologics announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) to aid in controlling high blood sugar for diabetes patients. Both products are available in various forms and can be substituted for the reference brand LANTUS®. Viatris emphasizes their commitment to improving access to affordable healthcare through a range of patient assistance programs, including copay and cash-pay options, effective from 2022.
Viatris Inc. (NASDAQ: VTRS) announced a $1 million donation to SBP, focusing on the Got Your Back Fund, which supports low-to-moderate income U.S. veterans in disaster recovery. This partnership aims to address housing instability exacerbated by COVID-19 by providing rebuilt and modified homes for veterans with disabilities. Viatris has contributed over $3 million to SBP since 2016, reinforcing its commitment to social support. The CEO emphasized the importance of funding in disaster recovery, particularly for veterans, while SBP's CEO expressed gratitude for Viatris's support in easing access to assistance.
Pittsburgh, Nov. 8, 2021 - Viatris reported Q3 2021 financial results with total revenues of $4.54 billion, U.S. GAAP net earnings of $312 million, and adjusted EBITDA of $1.70 billion. The company raised its 2021 financial guidance, projecting total revenues between $17.70 billion and $17.90 billion. Free cash flow is now expected to range between $2.40 billion and $2.60 billion. Viatris returned $266 million to shareholders in dividends and reduced debt by $1.9 billion in the first three quarters. A virtual investor event is scheduled for January 7, 2022.
On October 20, 2021, Viatris Inc. (NASDAQ: VTRS) announced that its interchangeable biosimilar Semglee® (insulin glargine-yfgn) will be listed as a preferred insulin brand on Express Scripts' National Preferred Formulary, impacting over 28 million lives. This decision aims to enhance patient access to affordable insulin, with both Semglee and its authorized counterpart set to launch before year-end 2021. The formulary change will take effect on January 1, 2022, promoting greater adoption of insulin among patients with diabetes.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
